MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen’s single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

<p><span style="font-weight: 400;">This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Authorization; There’s findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.</span></p>